首页|山东省化学药品辅料变更相关问题探讨和建议

山东省化学药品辅料变更相关问题探讨和建议

扫码查看
目的 分析山东省已上市化学药品药用辅料变更过程中常见问题,以期降低申请人变更研究的风险性,提升变更申报的规范性.方法 依据现行相关法律法规及指导原则的要求,结合行业现状和日常技术审评经验,对山东省备案申报过程中常见问题进行分析,并就问题提出思考和讨论.结果 山东省己上市化学药品药用辅料变更在变更识别和类别判断、备案公示内容填报、药用辅料证明性材料提供、药用辅料功能性指标对比、研究验证资料、稳定性研究等方面仍存在问题.结论 建议制剂持有人发挥主体责任,从研发阶段重视药品处方中辅料的研究,科学评估辅料变更,全面进行变更研究,保障药品全生命周期内的质量和疗效.
Discussion and Suggestions on Problems in Variation Research of Chemical Drug Excipients in Shandong Province
Objective To analyze the common problems in variation research of pharmaceutical excipients of post-approval chemical drug products in Shandong Province,in order to reduce the risks of variation research and improve the standardization of variation application.Methods Based on the requirements of current relevant laws,regulations,and guiding principles,combined with the industry status and technical review experience,the common problems in the filing and application process in Shandong Province were analyzed,and the thoughts and discussions on the problems were put forward.Results There were still problems with the identification and classification of variation of pharmaceutical excipients for post-approval chemical drugs in Shandong Province,as well as filling of content for record and publicity,supply of supporting materials and comparison of functional indicators of pharmaceutical excipients,research and validation data,and stability research,etc.Conclusion It is recommended that Marketing Authorization Holders fulfill their principal responsibility,pay attention to the research of pharmaceutical excipients from the research and development stage,scientifically evaluate verification of excipients,conduct comprehensive verification research,thus ensure the quality and efficacy of drugs throughout their entire life cycle.

post-approval chemical drug productpharmaceutical excipientpost-approval variationresearch and validation

董爱梅、周冲、武海军、刘福龙、刘军田

展开 >

山东省食品药品审评查验中心,山东济南 250014

已上市化学药品 药用辅料 上市后变更 研究验证

2024

食品与药品
山东省生物药物研究院

食品与药品

CSTPCD
影响因子:0.537
ISSN:1672-979X
年,卷(期):2024.26(6)